Live Breaking News & Updates on Associate Professor Jayesh Desai

Stay updated with breaking news from Associate professor jayesh desai. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

GLOBAL SARCOMA THERAPY NOW APPROVED FOR NEW ZEALAND PATIENTS

/PRNewswire/ Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that its portfolio therapy to treat rare soft tissue. ....

United States , New Zealand , Carlo Montagner , Denise Caruso , Jayesh Desai , Australia Therapeutic Goods Administration , Cancer Council Victoria Fact Sheet , European Medicines Agency Summary Of Product Characteristics , Zealand Sarcoma Association , Specialised Therapeutics , Associate Professor Jayesh Desai , Medical Oncologist , Deputy Chair , New Zealand Sarcoma Association , Executive Officer Dr Denise Caruso , Therapeutic Goods Administration , Specialised Therapeutics Asia , Executive Officer Mr Carlo Montagner , South East Asia , North America , South America , About Soft Tissue , Medsafe Approved Data , European Medicines Agency Summary , Molecular Spectrum ,

GLOBAL SARCOMA THERAPY NOW APPROVED FOR NEW ZEALAND PATIENTS

Globally regarded soft-tissue sarcoma therapy has been approved by Medsafe for New Zealand patients YONDELIS(trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine[1] SINGAPORE and AUCKLAND, New Zealand, Feb. 17, 2023 /PRNewswire/ Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that its portfolio therapy to treat rare soft tissue sarcomas has now been approved in New Zealand. Medsafe has approved the use of YONDELIS (trabectedin) "for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen".[2] YONDELIS (trabectedin) is used extensively around the world and has been shown to improve progression free survival[1]. News of the Medsafe registration has been welcomed by oncologists and the New Zealand sarcoma community, who say it means patients whose disease has progressed will have access to a new line of th ....

United States , New Zealand , Carlo Montagner , Denise Caruso , Jayesh Desai , Australia Therapeutic Goods Administration , Cancer Council Victoria Fact Sheet , European Medicines Agency Summary Of Product Characteristics , Zealand Sarcoma Association , Specialised Therapeutics , Associate Professor Jayesh Desai , Medical Oncologist , Deputy Chair , New Zealand Sarcoma Association , Executive Officer Dr Denise Caruso , Therapeutic Goods Administration , Specialised Therapeutics Asia , Executive Officer Mr Carlo Montagner , South East Asia , North America , South America , About Soft Tissue , Medsafe Approved Data , European Medicines Agency Summary , Molecular Spectrum ,

GLOBAL SARCOMA THERAPY NOW APPROVED FOR NEW ZEALAND PATIENTS

GLOBAL SARCOMA THERAPY NOW APPROVED FOR NEW ZEALAND PATIENTS
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , New Zealand , Carlo Montagner , Denise Caruso , Jayesh Desai , Australia Therapeutic Goods Administration , Cancer Council Victoria Fact Sheet , European Medicines Agency Summary Of Product Characteristics , Zealand Sarcoma Association , Specialised Therapeutics , Associate Professor Jayesh Desai , Medical Oncologist , Deputy Chair , New Zealand Sarcoma Association , Executive Officer Dr Denise Caruso , Therapeutic Goods Administration , Specialised Therapeutics Asia , Executive Officer Mr Carlo Montagner , South East Asia , North America , South America , Medsafe Approved Data Sheet , Prescribing Information , European Medicines Agency Summary , Product Characteristics , Product Information ,

GLOBAL SARCOMA THERAPY NOW APPROVED FOR NEW ZEALAND PATIENTS

Globally regarded soft-tissue sarcoma therapy has been approved by Medsafe for New Zealand patients YONDELIS® (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine[1] SINGAPORE and AUCKLAND, New Zealand, Feb. 17, 2023 /PRNewswire/ Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that its portfolio therapy to treat rare soft tissue sarcomas. ....

United States , New Zealand , Carlo Montagner , Denise Caruso , Jayesh Desai , Australia Therapeutic Goods Administration , Cancer Council Victoria Fact Sheet , European Medicines Agency Summary Of Product Characteristics , Zealand Sarcoma Association , Specialised Therapeutics , Associate Professor Jayesh Desai , Medical Oncologist , Deputy Chair , New Zealand Sarcoma Association , Executive Officer Dr Denise Caruso , Therapeutic Goods Administration , Specialised Therapeutics Asia , Executive Officer Mr Carlo Montagner , South East Asia , North America , South America , About Soft Tissue , Medsafe Approved Data , European Medicines Agency Summary , Council Victoria Fact Sheet , Molecular Spectrum ,

GLOBAL SARCOMA THERAPY NOW APPROVED FOR NEW ZEALAND PATIENTS

Globally regarded soft-tissue sarcoma therapy has been approved by Medsafe for New Zealand patients YONDELIS(trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine[1] SINGAPORE and AUCKLAND, New Zealand, Feb. 17, 2023 /PRNewswire/ Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that its portfolio therapy to treat rare soft tissue sarcomas has now been approved in New Zealand. Medsafe has approved the use of YONDELIS (trabectedin) "for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen".[2] YONDELIS (trabectedin) is used extensively around the world and has been shown to improve progression free survival[1]. News of the Medsafe registration has been welcomed by oncologists and the New Zealand sarcoma community, who say it means patients whose disease has progressed will have access to a new line of th ....

United States , New Zealand , Carlo Montagner , Denise Caruso , Jayesh Desai , Australia Therapeutic Goods Administration , Cancer Council Victoria Fact Sheet , European Medicines Agency Summary Of Product Characteristics , Zealand Sarcoma Association , Specialised Therapeutics , Associate Professor Jayesh Desai , Medical Oncologist , Deputy Chair , New Zealand Sarcoma Association , Executive Officer Dr Denise Caruso , Therapeutic Goods Administration , Specialised Therapeutics Asia , Executive Officer Mr Carlo Montagner , South East Asia , North America , South America , About Soft Tissue , Medsafe Approved Data , European Medicines Agency Summary , Molecular Spectrum ,